Clinical trial / 2005
Green tea extract shows minimal clinical activity in hormone refractory prostate cancer.
Nineteen patients with hormone refractory prostate cancer received 250 mg green tea extract capsules twice daily in a prospective clinical trial. Of the 15 participants who finished at least 2 months of treatment, 9 showed progressive disease within 2 months. The remaining 6 individuals developed disease progression after an additional 1 to 4 months of therapy, demonstrating minimal clinical efficacy.
- Study type
- Prospective clinical trial
- Who was studied
- 19 patients with hormone refractory prostate cancer
- What was measured
- Prostate-specific antigen or measurable disease progression
THE PAPER
A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.
Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V. Urol Oncol, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.